Cancer drug development award given to Jean-Charles Soria
Share

IMAGE: This is Prof. Jean-Charles Soria. view more 

Credit: ESMO

LUGANO, 12 February 2018 – The TAT 2018 Honorary Award for cancer drug development has been granted to Professor Jean-Charles Soria, for his pioneering role in cancer drug development across molecular targeted agents, precision medicine, and immunotherapy. (1) The award will be presented during the International Congress on Targeted Anticancer Therapies (TAT) 2018, to be held in Paris, France, 5-7 March. (2)

The TAT Honorary Award was established in the early 1990s to acknowledge distinguished cancer drug development experts who have devoted a major part of their careers to the discovery and development of better anticancer medicines.

Over the past 15 years, Soria has pushed forward the molecular enrichment of patient populations in early clinical trials. This has increased response rates and been a key factor in the successful development of a number of drugs, including osimertinib for lung cancer. He has launched large precision medicine trials in both early drug development and lung cancer.

In the immunotherapy field, Soria has contributed to first-in-man trials of atezolizumab and pembrolizumab, which have changed the treatment of cancer. He was deeply committed to obtaining paired tumour biopsies for a better understanding

read more...


Article originally posted at
www.eurekalert.org

Click here for the full story


CategoryAggregator News

© 2017 - LIFE EXTENSION ADVOCACY FOUNDATION
Privacy Policy / Terms Of Use

Powered by MMD